USA flag logo/image

An Official Website of the United States Government

Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral…

Award Information

Agency:
Department of Agriculture
Branch:
N/A
Award ID:
77596
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
2006-00528
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MOLECULAR TARGETING TECHNOLOGIES, INC.
833 LINCOLN AVE, UNIT 9 WEST CHESTER, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife
Agency: USDA
Contract: 2006-33610-16801
Award Amount: $79,700.00
 

Abstract:

Extensive worldwide reservoirs of rabies virus (RV) in wildlife and stray dogs continue to pose a serious risk of lethal infection of humans and cause a high economic burden. Immunization of wildlife and stray dogs with live vaccines is the only effective method to control and eventually eliminate rabies in carnivore species worldwide. In this application we propose to select canine adenovirus type-2 (CAV2) clones that optimally express the rabies virus (RV) G protein from previously engineered replication-competent CAV 2 - RVG constructs. These selected CAV 2-RVG viruses will be evaluated for safety and efficacy in laboratory animals as an initial proof of concept.

Principal Investigator:

Jeffrey A. Mattis
Sr. Vice President, Scientific Affairs
6107387938
jmattis@mtarget.com

Business Contact:

Koon Pak
President and CEO
6107387938
cpak@mtarget.com
Small Business Information at Submission:

Molecular Targeting Technologies, Inc.
882 S. Matlack Street Suite 105 West Chester, PA 19382

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No